Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMS-D001 tablets for moderate to severe plaque psoriasis (Phase II/III)
ChiCTR2600120745Phase 3Not yet recruiting
- Sponsor
- Shandong First Medical University Affiliated Dermatology Hospital
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of CMS-D001 in plaque psoriasis (6 arms), sponsored by Shandong First Medical University Affiliated Dermatology Hospital. Primary endpoints: Phase II: PASI 75 response at Week 12, Phase III: PASI 75 response at Week 16 and 1 more. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
CMS-D001
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on ChiCTR2600120745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600120745.